Posted by Michael Wonder on 01 Jul 2020
Sun BioPharma receives FDA fast track designation for SBP-101
30 June 2020 - Sun BioPharma today announced receipt of fast track designation from the U.S. FDA for its lead product, SBP-101, being developed for first-line treatment of patients with metastatic pancreatic ductal adenocarcinoma when administered in combination with gemcitabine and nab-paclitaxel.
SBP-101 is currently being evaluated in a Phase 1a/1b clinical trial of patients with previously untreated metastatic pancreatic ductal adenocarcinoma at sites in the United States and Australia.
